Key facts
- AQEMIA’s last known valuation is $243.6M (Dec 2024).
- It has raised $69.5M; the latest was Grant ($7.4M) in Apr 2025.
- Notable investors include Bpifrance, La French Tech, Agoranov, Cathay Innovation, Cathay Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AQEMIA
- ·The full record, as it builds
Funding rounds
No funding rounds for AQEMIA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AQEMIA
Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's platform combines machine learning and quantum-inspired statistical mechanics algorithms to generate lead-like molecules for a given target, enabling researchers to efficiently and accurately predict the affinity between drug candidates and therapeutic targets.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 84
- Website
- aqemia.com/
- Ownership
- Privately Held (backing)
AQEMIA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AQEMIA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AQEMIA in its N-PORT filings yet. We sweep new filings monthly.